CA2890194A1 - Sels d'amine de laquinimod - Google Patents
Sels d'amine de laquinimod Download PDFInfo
- Publication number
- CA2890194A1 CA2890194A1 CA2890194A CA2890194A CA2890194A1 CA 2890194 A1 CA2890194 A1 CA 2890194A1 CA 2890194 A CA2890194 A CA 2890194A CA 2890194 A CA2890194 A CA 2890194A CA 2890194 A1 CA2890194 A1 CA 2890194A1
- Authority
- CA
- Canada
- Prior art keywords
- laquinimod
- monoethanolamine
- lysine
- choline hydroxide
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723495P | 2012-11-07 | 2012-11-07 | |
US61/723,495 | 2012-11-07 | ||
PCT/US2013/067686 WO2014074381A1 (fr) | 2012-11-07 | 2013-10-31 | Sels d'amine de laquinimod |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2890194A1 true CA2890194A1 (fr) | 2014-05-15 |
Family
ID=50622908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2890194A Abandoned CA2890194A1 (fr) | 2012-11-07 | 2013-10-31 | Sels d'amine de laquinimod |
Country Status (15)
Country | Link |
---|---|
US (1) | US8975279B2 (fr) |
EP (1) | EP2916915A4 (fr) |
JP (1) | JP2015535287A (fr) |
KR (1) | KR20150091077A (fr) |
CN (1) | CN104955522A (fr) |
AR (1) | AR093335A1 (fr) |
AU (1) | AU2013341506A1 (fr) |
BR (1) | BR112015010193A2 (fr) |
CA (1) | CA2890194A1 (fr) |
EA (1) | EA201590788A1 (fr) |
HK (2) | HK1212936A1 (fr) |
IL (1) | IL238535A0 (fr) |
MX (1) | MX2015005632A (fr) |
TW (1) | TW201422588A (fr) |
WO (1) | WO2014074381A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
CN106573014A (zh) | 2014-04-29 | 2017-04-19 | 梯瓦制药工业有限公司 | 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US20180071376A1 (en) | 2015-03-23 | 2018-03-15 | The Brigham And Women`S Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
US20210220481A1 (en) | 2018-08-03 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biocompatible tolerogenic nanoparticles |
EP3886893A1 (fr) | 2018-11-27 | 2021-10-06 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Nanoparticules servant à préparer des lymphocytes b régulateurs |
KR20210124855A (ko) | 2020-04-07 | 2021-10-15 | 주식회사 엘에스파마 | 고미가 차폐된 디클로페낙을 함유하는 약제학적 조성물 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
CA2376202C (fr) | 1999-06-07 | 2008-11-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Preparation et forme galenique comprenant un compose actif acido-labile |
CN100390148C (zh) | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20060188568A1 (en) | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
RU2008137765A (ru) | 2006-03-16 | 2010-04-27 | Генентек, Инк. (Us) | Способы лечения волчанки с помощью антител к cd4 |
ES2377149T3 (es) * | 2006-06-12 | 2012-03-22 | Teva Pharmaceutical Industries Limited | Preparaciones de laquinimod estables |
EP2392320A1 (fr) | 2006-08-17 | 2011-12-07 | University Of Chicago | Traitement de maladies inflammatoires |
US20100260716A1 (en) | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
EP2977049A1 (fr) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Préparations de laquinimod stables |
EP2318371A2 (fr) * | 2008-07-01 | 2011-05-11 | Actavis Group PTC EHF | Nouvelles formes à l état solide de laquinimod et de son sel de sodium |
CN104311486A (zh) | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
RS54328B1 (en) | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS |
PL2458992T3 (pl) | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
SI2467372T1 (sl) | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda |
WO2011086470A1 (fr) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Traitement de la sclérose en plaques |
DK2542079T3 (da) | 2010-03-03 | 2014-08-25 | Teva Pharma | Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat |
CN102781239B (zh) | 2010-03-03 | 2015-01-21 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮关节炎 |
JP2013535437A (ja) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたn−エチル−n−フェニル−1,2−ジヒドロ−4−ヒドロキシ−5−クロロ−1−メチル−2−オキソキノリン−3−カルボキサミド、その塩および使用 |
EA201390074A1 (ru) | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения |
EP2463289A1 (fr) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK |
EA201390827A1 (ru) | 2010-12-07 | 2013-12-30 | Тева Фармасьютикал Индастриз Лтд. | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом |
EP2537517A1 (fr) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide enrichie au deuterium |
IN2014MN00333A (fr) | 2011-07-28 | 2015-09-25 | Teva Pharma | |
JP2014521659A (ja) | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
WO2013055907A1 (fr) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Traitement de la sclérose en plaques par combinaison de laquinimod et de fingolimod |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
TW201347762A (zh) | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
TW201350467A (zh) * | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
WO2014004733A1 (fr) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition pour la néphropathie lupique et ses méthodes de fabrication et d'utilisation |
AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療***素受體型1(cb1)媒介之疾病之拉喹莫德(laquinimod) |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
-
2013
- 2013-10-31 AU AU2013341506A patent/AU2013341506A1/en not_active Abandoned
- 2013-10-31 US US14/068,599 patent/US8975279B2/en not_active Expired - Fee Related
- 2013-10-31 WO PCT/US2013/067686 patent/WO2014074381A1/fr active Application Filing
- 2013-10-31 CN CN201380058339.0A patent/CN104955522A/zh active Pending
- 2013-10-31 CA CA2890194A patent/CA2890194A1/fr not_active Abandoned
- 2013-10-31 KR KR1020157014911A patent/KR20150091077A/ko not_active Application Discontinuation
- 2013-10-31 MX MX2015005632A patent/MX2015005632A/es unknown
- 2013-10-31 JP JP2015540779A patent/JP2015535287A/ja active Pending
- 2013-10-31 EP EP13852663.7A patent/EP2916915A4/fr not_active Withdrawn
- 2013-10-31 EA EA201590788A patent/EA201590788A1/ru unknown
- 2013-10-31 BR BR112015010193A patent/BR112015010193A2/pt active Search and Examination
- 2013-11-01 AR ARP130104013A patent/AR093335A1/es unknown
- 2013-11-05 TW TW102140149A patent/TW201422588A/zh unknown
-
2015
- 2015-04-30 IL IL238535A patent/IL238535A0/en unknown
-
2016
- 2016-01-25 HK HK16100794.0A patent/HK1212936A1/zh unknown
- 2016-03-21 HK HK16103249.5A patent/HK1215210A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20140128430A1 (en) | 2014-05-08 |
AU2013341506A1 (en) | 2015-06-04 |
JP2015535287A (ja) | 2015-12-10 |
BR112015010193A2 (pt) | 2017-07-11 |
MX2015005632A (es) | 2016-02-05 |
EA201590788A1 (ru) | 2015-12-30 |
US8975279B2 (en) | 2015-03-10 |
EP2916915A4 (fr) | 2016-06-22 |
CN104955522A (zh) | 2015-09-30 |
HK1215210A1 (zh) | 2016-08-19 |
WO2014074381A1 (fr) | 2014-05-15 |
HK1212936A1 (zh) | 2016-06-24 |
KR20150091077A (ko) | 2015-08-07 |
IL238535A0 (en) | 2015-06-30 |
AR093335A1 (es) | 2015-06-03 |
TW201422588A (zh) | 2014-06-16 |
EP2916915A1 (fr) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2890194A1 (fr) | Sels d'amine de laquinimod | |
US10519176B2 (en) | Crystalline forms | |
JP6010154B2 (ja) | L−オルニチンフェニルアセテートおよびその製造方法 | |
ES2732845T3 (es) | Sales de Aramchol | |
JP6028016B2 (ja) | リナグリプチンベンゾエートの多形体 | |
AU2015221466B2 (en) | L-ornithine phenyl acetate and methods of making thereof | |
AU2011307608B2 (en) | Crystalline naloxol-PEG conjugate | |
AU2017336889B2 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
KR20150035998A (ko) | 리팍시민 및 아미노산을 포함하는 약학적 조성물, 이의 제조방법 및 용도 | |
JP2016525528A (ja) | 非晶質形態のダサチニブの塩 | |
JP2023553930A (ja) | トレブルチニブの結晶形態、その製造方法、およびその使用 | |
JP7303821B2 (ja) | ピリミジニルアミノ-ピラゾール化合物の多形体及び固体形態、ならびに製造方法 | |
KR101962189B1 (ko) | 아리피프라졸의 공결정 및 그의 제조방법 | |
US20080234286A1 (en) | Stable amorphous imatinib mesylate and production process therefor | |
JP7163280B2 (ja) | ムスカリン性アセチルコリン受容体アゴニストの結晶性多形 | |
CN115124456B (zh) | 哌马色林药用盐、制备方法、含其的药物组合物及应用 | |
WO2022199707A1 (fr) | Sel pharmaceutiquement acceptable de pimavansérine, procédé de préparation associé, composition pharmaceutique la contenant et utilisation associée | |
US20210230213A1 (en) | Aramchol salts | |
US20200277326A1 (en) | Aramchol salts | |
CN117980295A (zh) | 一种依洛西巴特晶型ii及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20181031 |